Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seres Therapeutics poised for FDA approval with strong pipeline progress

Seres Therapeutics is well-positioned for potential FDA approval of SER-109, backed by strong Phase III efficacy and safety data. The company's financial stability and strategic collaborations underscore a focused approach towards commercial success. Addressing key challenges and leveraging opportunities in product development and market entry will be crucial for Seres Therapeutics' future growth.

Seres Therapeutics secures FDA approval for VOWST, eyes commercial success

Seres Therapeutics is poised for success with FDA approval of VOWST and positive study results for SER-155. The company faces challenges in ensuring consistent engraftment and optimizing operational efficiencies. Opportunities lie in commercializing VOWST and advancing microbiome therapeutics.

Seres Therapeutics reports robust Q2 earnings, eyes VOWST growth

Seres Therapeutics had a strong Q2 2023, propelled by VOWST approval and positive sales performance, positioning the company for continued growth.
While facing challenges like Medicare affordability issues and net losses, Seres remains optimistic about VOWST's potential and profitability trajectory.
By capitalizing on opportunities in education, expansion, and efficiency, Seres aims to drive VOWST adoption, enhance market presence, and achieve financial success.

Seres Therapeutics excels in Q3 with VOWST launch success

Seres Therapeutics reported a strong Q3 performance with the successful VOWST launch, despite a net loss. The company's restructuring focuses on VOWST's growth and long-term sustainability. Challenges include optimizing VOWST sales and navigating reimbursement differences.

Seres Therapeutics excels in 2023 with VOWST launch and financial focus

Seres Therapeutics had a strong 2023, marked by successful product launches, financial discipline, and promising development in microbiome therapeutics.
The company's strengths include innovation, financial stability, strong leadership, and efficient budget management, positioning them for future growth.
Challenges include sustaining momentum, securing funding for advancement, meeting regulatory expectations, and ensuring positive patient experiences.
Opportunities lie in continued growth, partnerships, strategic funding, innovation, and establishing a compelling market narrative.
Overall, Seres Therapeutics is well-positioned for success in the microbiome therapeutics market, with a focus on product development and financial discipline.

Seres Therapeutics reports robust Q1 sales and advances pipeline growth

Seres Therapeutics demonstrated strong sales performance with VOWST net sales reaching $10.1 million in Q1 2024.
The company's focus on commercialization of VOWST and advancement of microbiome therapeutic candidates like SER-155 shows promise for future growth.
Challenges in pricing, inventory management, and funding are being addressed, while opportunities in new patient populations and strategic partnerships are being explored.

Seres Therapeutics sells VOWST assets, reports strong Q2 earnings

Seres Therapeutics' Q2 performance was marked by a strategic asset sale, strong financial results, and progress in key pipeline programs. The company's focus on transformative therapies and data-driven pipeline prioritization positions it well for future growth and impact in the healthcare sector.

Seres Therapeutics reports Q3 loss but sees growth opportunities ahead

Seres Therapeutics faced a net loss in Q3 2024 but maintained strong cash reserves for operations into Q4 2025.
Positive results from SER-155 and the VOWST sale present opportunities for growth and addressing bacterial infections in patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--New data from microbiome and metabolomic endpoints provide mechanistic support of Seres' positive Phase 3 results in recurrent C. difficile infection.

Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days. About Seres Therapeutics Sere

Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company's Phase 1b trial of SER-287 in patients with active mild-to-moderate ulcerative colitis (UC), most of whom were failing current therapies. The study results demonstrated that SER-287 administration was associated with positive impacts on clinical remission, endoscopic improvement, modulation of the gastrointestinal microbiome, and a favorable tolerability

Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology

CRISPR Therapeutics

Denali Therapeutics

NantKwest

Rocket Pharma

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

5 Medical Outperformers That Might Lose Steam in 2021

BioNTech SE

Celldex Therapeutics

Co-Diagnostics

Cardiff Oncology

Moderna

Nestle SA

Novavax

Trillium Therapeutics

Vaxart

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

These Were the 10 Best Healthcare Stocks of 2020

Inovio Pharmaceuticals

Pfizer

Twist Bioscience Corp

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020

Late August spike means share price moves from below $5 to more than $30. Capital raising and Nestle agreement raised $264 million.

Seres Therapeutics: Microbiomics Back In The Game

Seres has seen +863% upside YTD on the back of positive top-line data in their phase 3 SER-109 study, which helps prove their microbiome hypotheses. Management have strengthened the cash position and the balance sheet, with key collaborations with Nestle and via equity capital, thus runaway is now over 2 years.

Seres Therapeutics' SER-109 Has Accelerated Growth Potential

Seres has appreciated over 800% in the last one year. Despite strong phase 3 efficacy data, the FDA has asked for additional safety data.

Seres: An Interesting Late-Stage Microbiome Development Company

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB) today reported financial results from the third quarter ended September 30, 2020, and provided business updates. “Supported by our positive, highly significant SER-109 Phase 3 results, we expect SER-109 to be the first-ever microbiome therapy approved by the U.S. FDA. Following those remarkable SER-109 study data and a significant capital infusion, Seres is in the midst of transformational growth toward becoming a comme

Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). SER-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation central to ulcerative colitis and induce clinical remission in patients suffering from active UC. SER-301 is designed to modify the gast

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced that management will host a conference call and live audio webcast on November 9, 2020 at 8:30 a.m. ET to discuss third quarter 2020 results and provide a general business update. To access the conference call, please dia

Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M. Gansler as Executive Vice President, Chief People Officer (CPO). “Supported by our highly positive SER-109 Phase 3 results, we are expanding our capabilities and strengthening the Seres team as we move towards what we expect to be the first-ever FDA-ap

Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the presentation of previously announced positive Phase 3 results from the ECOSPOR III trial of SER-109 at the Virtual American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 23-28, 2020. New data to be presented in Seres’ late-breaker oral presentation show that SER-109 led to a sustained highly statistically significant absolute reduction in C. difficile infection recur

Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting 

AutoWeb

Fidelity NASDAQ Composite Index

Invesco QQQ

Direxion NASDAQ-100 Equal Weighted Index Shares

Sunworks

The tech-heavy Nasdaq index posted its best third quarter in 10 years this year.

Nasdaq's Best Third Quarter in 10 Years: Best ETFs & Stocks

Adaptimmune Therapeutics

Chemocentryx

Kodiak Sciences Inc

Myovant Sciences

Sorrento Therapeutics Inc

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

7 ‘A-Rated’ Aggressive Biotech Stocks to Gamble On

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T. A webcast of the presentation will be available under the “Investors and Media” section of Seres’ website and will be archived for 21 days. About Seres Therapeutics Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company deve

Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

Seres Therapeutics to Present at Upcoming Investor Conferences

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

A small Boston-area biotech hopes to usher in a new era in disease treatment by getting regulatory approval for its microbiome drug.

Seres Seeks Approval of First Microbiome Drug

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--Seres Therapeutics, Inc.

Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock

A major investor boosted its stake in the microbiome therapeutics leader.

Why Seres Therapeutics Stock Surged Today

Seres Therapeutics stock slipped early Thursday after the small biotech priced and boosted the size of a stock offering two days after its positive drug trial news sent MCRB stock soaring.
The post Tiny Biotech Follows Big Stock Jump With Stock Offering Pricing; MCRB Slips appeared first on Investor's Business Daily.

News for Seres Therapeutics Stock (MCRB)